Sinopharm Group Co has the GF Score of 73, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Sinopharm Group Co
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Sinopharm Group Co (OTCPK:SHTDY) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Sinopharm Group Co GF Score Related Terms
SHTDY vs MCK, CAH, COR: GF Score Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co GF Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's GF Score distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's GF Score falls into.
Sinopharm Group Co (SHTDY) has a GF Score of 73 as of Jun. 29, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Sinopharm Group Co and its competitors. This is 10% below median its historical median of 81.00. Over the past decade, Sinopharm Group Co's GF Score has ranged from 36.00 to 96.00.
Is Sinopharm Group Co's GF Score too high?
Sinopharm Group Co's current GF Score of 73 is 10% below median its 10-year median of 81.00. Over the past 10 years, this metric has ranged from a low of 36.00 to a high of 96.00. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's GF Score compare to MCK and CAH?
Sinopharm Group Co's GF Score of 73 can be compared against companies in the Medical Distribution industry. Historically, Sinopharm Group Co's own GF Score has ranged from 36.00 to 96.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Distribution company?
A good GF Score depends on the Medical Distribution industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current GF Score is 73, which is 10% below median its own 10-year median of 81.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.40, compared to a current price of $10.14 — trading 24.3% below its estimated fair value. The current GF Score is 73, which is 10% below median its 10-year median of 81.00. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current GF Score is 73 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.14 is trading 24.3% below its estimated GF Value™ of $13.40.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
GF Score: 73 (10% below median its 10-year median of 81.00)
GF Value™: $13.40 vs. price of $10.14 (24.3% below fair value)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 